Thomas Bo Jensen
Novo Nordisk (Denmark)(DK)Aarhus School of Architecture(DK)
Publications by Year
Research Areas
Venous Thromboembolism Diagnosis and Management, Diabetes Treatment and Management, Historical and Archaeological Studies, Health Systems, Economic Evaluations, Quality of Life, Biosimilars and Bioanalytical Methods
Most-Cited Works
- → Shift From Adalimumab Originator to Biosimilars in Denmark(2020)87 cited
- → Obesity is a risk factor for atrial fibrillation among fertile young women: a nationwide cohort study(2013)77 cited
- → Familial clustering of myocardial infarction in first-degree relatives: a nationwide study(2013)72 cited
- → The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars(2019)58 cited
- → Hormone Replacement Therapy and Risk of New-Onset Atrial Fibrillation after Myocardial Infarction - A Nationwide Cohort Study(2012)51 cited
- → Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort study(2013)49 cited